Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

Fig. 5

Anti-tumor activity of LC53-0110 in mice bearing human multiple myeloma xenografts. a The LC and reference compounds were orally administered twice a week (BIW) or once a week (QW) in mice bearing MM.1S xenografts as indicated. The mean tumor volume for each animal in the vehicle and treatment groups was determined during the study. Data points, mean+/−SE (n = 6). b LC53-0110 was orally administered twice a week or once a week in mice bearing RPMI8226 xenografts as indicated, and reference compounds were intravenously administered twice a week. The mean tumor volume for each animal in the vehicle and treatment groups was determined during the study. Data points, mean+/−SE (n = 8)

Back to article page